Hyaluronic acid may reduce incidence of intrauterine adhesions and improve fertility outcomes after intrauterine surgery: Study

Hyaluronic acid may reduce the incidence of intrauterine adhesions and improve fertility outcomes after intrauterine surgery suggests a study published in the American Journal of Obstetrics & Gynecology.

This study aimed to determine the efficacy and safety of hyaluronic acid gel for the prevention of intrauterine adhesions and improved fertility after intrauterine surgery. Randomized controlled trials that reported intrauterine adhesion and fertility outcomes among women who used hyaluronic acid after intrauterine surgery. The risk of bias was assessed using criteria of the Cochrane Handbook, and the quality of the evidence was evaluated using the Grades of Recommendation, Assessment, Development, and Evaluation system. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. A trial sequential analysis was conducted to assess the outcomes, and Stata 14 was used for sensitivity analyses and publication bias analyses. Results: Data from 16 randomized controlled trials involving 2359 patients were extracted and analyzed. The analysis revealed that hyaluronic acid reduced the incidence of intrauterine adhesion (risk ratio, 0.53; 95% confidence interval, 0.42–0.67; I2=48%) and improve pregnancy rates (risk ratio, 1.24; 95% confidence interval, 1.02–1.50; I2=0%). A subgroup analysis was conducted to evaluate factors that influence the effect of hyaluronic acid on the incidence of intrauterine adhesion. It was found that a small volume of hyaluronic acid reduced the incidence of intrauterine adhesions. Hyaluronic acid exhibited a protective effect among patients who underwent various intrauterine surgeries and who had different gynecologic medical histories. The protective effect was statistically significant after a follow-up of 6 to 12 weeks. The results of the trial sequential analysis indicated that the effect of hyaluronic acid on the incidence of mild intrauterine adhesions, pregnancy rates, live birth rates, and miscarriage rates after intrauterine surgery may be inconclusive and thus further evaluation is required in the form of additional clinical trials. However, the remaining effects were found to be verifiable and did not require more clinical trials for confirmation. Hyaluronic acid can safely and effectively reduce the incidence of intrauterine adhesions and may improve fertility outcomes.

Reference:

Luo Y, Sun Y, Huang B, Chen J, Xu B, Li H. Effects and safety of hyaluronic acid gel on intrauterine adhesion and fertility after intrauterine surgery: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials. Am J Obstet Gynecol. 2024 Jul;231(1):36-50.35. doi: 10.1016/j.ajog.2023.12.039. Epub 2024 Jan 6. PMID: 38191020.

Keywords:

Hyaluronic acid, reduce, incidence, intrauterine, adhesions, improve, fertility, outcomes, intrauterine, surgery, study, American Journal of Obstetrics & Gynecology, Luo Y, Sun Y, Huang B, Chen J, Xu B, Li H.

Powered by WPeMatico

Sanofi Healthcare Gets CDSCO Panel Nod to Import and Market Belumosudil Tablets

New Delhi: Noting an unmet medical need, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to the drug major Sanofi Healthcare to import and market Belumosudil tablets 200 mg, with a condition to conduct a Phase IV clinical trial (CT) study involving high-volume transplant centers (more than 100) across the country.

This came after Sanofi Healthcare presented the published literature on the post-marketing safety data of Belumosudil tablets 200 mg from other countries, along with the Phase IV CT protocol, before the committee.

In regard to the above proposal, the expert panel noted that the proposed drug is an orphan drug approved in other countries and falls under unmet medical need. An orphan drug is a pharmaceutical agent that is developed to treat certain rare medical conditions.

Belumosudil is an oral inhibitor of rho-associated coiled-coil-containing protein kinases (ROCK) used in the treatment of chronic graft-versus-host disease (GVHD).

Chronic graft-versus-host disease (GVHD) is a life-threatening complication of allogeneic hematopoietic stem cell transplantation in which the transplanted donor T-cells recognize the recipient’s tissues as foreign and mount an immune response.

Belumosudil is an inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a protein that plays a vital role in the pathogenesis of immune and fibrotic diseases. The inhibition of ROCK2 has been shown to resolve immune dysregulation by down-regulating pro-inflammatory Th17 cells and up-regulating regulatory T-cells by manipulating the phosphorylation of STAT3 and STAT5.

Belumosudil was first approved by the FDA in July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and failed at least two prior lines of systemic therapy. In July 2022, Belumosudil was approved by Health Canada under the brand name RHOLISTIQ to treat the same condition in adult and pediatric patients 12 years of age or older.

At the recent SEC meeting for Hematology held on June 18, 2023, the expert panel reviewed the published literature on post marketing safety data of Belumosudil tablets 200 mg, of other countries along with Phase IV CT protocol.

Noting that the proposed drug is an orphan drug approved in other countries and that it falls under unmet medical need, the committee agreed to the Phase III CT waiver.

After detailed deliberation, the committee recommended the grant of permission to import and market Belumosudil tablets 200 mg, with a condition to conduct a Phase IV CT study involving high-volume transplant centers (more than 100) across the country.

Accordingly, the expert panel suggested that the firm submit a Phase IV study protocol within 3 months from the date of approval to CDSCO for further evaluation by the committee.

Also Read: Zydus Lifscience Gets CDSCO Panel Nod to Manufacture, Market Nivolumab for Metastatic Non-small Cell Lung Cancer

Powered by WPeMatico

Roche to halt lung cancer treatment trial

Basel: Roche has announced that the phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial (first-line) treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, did not meet its primary endpoints of progression-free survival (PFS) at its primary analysis with a hazard ratio (HR) of 1.27 [95% CI: 1.02,1.57] and overall survival (OS) at its first interim analysis with a HR of 1.33 [95% CI: 1.02, 1.73], which was immature.

The combination of tiragolumab plus Tecentriq and chemotherapy showed reduced efficacy in both PFS and OS compared to the comparator arm in the intent-to-treat population, which includes the phase II and phase III cohorts. The overall safety profile remains consistent with the safety profile previously observed for the combination of tiragolumab plus Tecentriq and chemotherapy, and no new or unexpected findings were identified.

“Based on these results, patients and investigators will be unblinded and we intend to halt the study. A communication will be sent to the investigators and results will be shared with health authorities and subsequently presented at an upcoming medical meeting,” the Company stated.

“These results are disappointing as it was our hope that this combination might yield improved outcomes for people living with metastatic non-squamous lung cancer,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “We are thankful to all of the patients and healthcare professionals involved in the study, and we will leverage the learnings to inform our scientific understanding of the anti-TIGIT pathway and new avenues in cancer research.”

Ongoing phase III studies are investigating treatment settings and indications distinct from SKYSCRAPER-06. Based on today’s results, we will evaluate any relevant changes needed to the ongoing tiragolumab programme.

Read also: Roche Vabysmo prefilled syringe bags USFDA nod for three causes of vision loss

Powered by WPeMatico

Rourkela Sub Divisional Railway Hospital faces Inadequate Infrastructure, Staff Shortage

Rourkela: The sub-divisional
railway hospital of South Eastern Railway (SER) located at Bondamunda in
Rourkela is grappling with a severe lack of infrastructure and insufficient
medical staff, leaving it unable to provide even basic healthcare services to
the nearly 8,000 railway employees and their families who rely on it.

The hospital, designed to
serve around 6,000 SER employees stationed at Bondamunda and Rourkela along
with their families, has a capacity of 65 beds but falls drastically short in
delivering adequate medical care, reports The New Indian Express. According to sources, the
hospital lacks specialist doctors and a functional pathological testing
facility. Currently, there are only three MBBS doctors available, who not only
handle patient care and emergencies but also juggle administrative responsibilities
on a rotational basis. 

The hospital’s equipment
is outdated and inadequate for modern medical needs. The X-ray machine is old
and unreliable, and the facility lacks in-house pathological testing. For basic
pathological tests, a private technician visits once a day to collect samples
for external testing, leaving no provision for urgent tests, reports the Daily.

Moreover, the hospital’s
operation theatre remains unusable due to the absence of a surgeon, forcing the
immediate referral of emergency and accident cases to other hospitals such as
Ispat General Hospital (IGH), Rajasthan Seva Sadan, and CWS Hospital. A private
gynaecologist provides consultation services only on a case-by-case basis,
further highlighting the hospital’s limitations.

According to the Daily, D
Chandrasekhar Rao, the secretary of the Bondamunda unit of SER Men’s Congress
(SERMC), expressed concerns over the hospital’s inadequate staffing and
facilities. The hospital, which is supposed to have seven doctors as per the
sanctioned strength, is currently managed by only three.

Rao emphasized that
without advanced medical facilities, the hospital is only able to treat common
ailments like fever, cold, cough, blood pressure issues, and blood sugar
fluctuations. During a visit by the principal chief medical officer from SER
headquarters in Kolkata, the staff urgently requested the deployment of more
doctors and an upgrade in facilities to better serve the community.

The jurisdiction of this
sub-divisional railway hospital extends to the entire districts of Sundargarh
and Jharsuguda, amplifying the need for more comprehensive medical services.
Former Union Minister and ex-Rourkela MLA, Dilip Ray, recently met with Union
Railway Minister Ashwini Vaishnaw to request an upgrade of the hospital’s
facilities. Ray reported receiving a positive assurance from the minister, who
acknowledged the critical situation and promised to address the hospital’s
shortcomings. Additionally, the Divisional Railway Manager (DRM) of Chakradharpur
Division of SER, Arun Jatoh Rathod, conducted a recent visit to assess the
hospital’s conditions and needs. 

Powered by WPeMatico

Doctors at Amrita Hospital conduct first robot-assisted surgery for rare colon tumour

In a groundbreaking surgical feat, a 67-year-old man from Uzbekistan was treated for his rare colonic tumour at Amrita Hospital, Faridabad marking the world’s first robot-assisted surgery for the condition.

The patient, from Uzbekistan, had a special condition where his liver and colon were positioned differently (situs inversus partial) and he had a malignant tumour in this mispositioned colon.

For more information, click on the link below:

Amrita Hospital Doctors Perform First Robot-Assisted Surgery For Rare Colon Tumour In 67-Year-Old Uzbekistan Man

Powered by WPeMatico

Health Bulletin 08/ July/ 2024

Here are the top health stories for the day:

Amrita Hospital conducts first robot-assisted Colon tumour surgery on 67-year-old man

In a groundbreaking surgical feat, a 67-year-old man from Uzbekistan was treated for his rare colonic tumour at Amrita Hospital, Faridabad marking the world’s first robot-assisted surgery for the condition.

The patient, from Uzbekistan, had a special condition where his liver and colon were positioned differently (situs inversus partial) and he had a malignant tumour in this mispositioned colon.

For more information, click on the link below:

Amrita Hospital Doctors Perform First Robot-Assisted Surgery For Rare Colon Tumour In 67-Year-Old Uzbekistan Man

Government Approves 113 New Medical Colleges; 22 in UP, 14 in Maharashtra

A significant milestone has been achieved with the approval of 113 new medical colleges by the National Medical Commission (NMC), with the highest number of approvals in Uttar Pradesh, officials announced.

Uttar Pradesh has been granted approval to establish 22 new medical colleges, followed by Maharashtra with 14, Rajasthan with 12, Telangana with 11, West Bengal with 8, Madhya Pradesh with 7, Andhra Pradesh with 7, Karnataka with 5, Tamil Nadu with 5, and Kerala with 2.

NEET 2024 counselling postponed; likely to begin at month-end: Report

Even though the National Eligibility-Entrance Test Undergraduate (NEET UG) 2024 counselling was scheduled to commence on 6th July 2024, the counselling process has now been deferred until further notice.

This comes after the Supreme Court had earlier denied postponing the counselling schedule of the NEET UG 2024 while considering the pleas alleging paper leak and demanding a re-conduction of the examination. The counselling session was expected to start on July 6 even though the Medical Counselling Committee had not shared any detailed notification and schedule for it.

For more information, click on the link below:

Postponed! NEET 2024 Counselling Likely To Begin At Month End, Schedule Not Finalised Yet: Report


DCI sets deadline for dental colleges to submit MDS student details 

A letter has been issued by the Deputy Secretary, Dental Council of India (DCI), to the principals of all dental colleges in India regarding uploading the details of students admitted to MDS/PG Diploma courses in dental colleges for the academic session 2024-25 on the official website of DCI.

Through the letter, Mr Kumar has stated that as per the Counseling Schedule issued by the Medical Counselling Committee (MCC) for Online Counseling (Allotment Process) for National Eligibility- Entrance Test (NEET) 50% AIQ and 100% Deemed / Central Universities & State Quota seats for MDS Courses for the academic year 2024, the MCC declared that the last date for joining is 14th September 2024 and the commencement of academic session for PG Courses is 1st August, 2024 for the academic year 2024-25.

For more information, click on the link below:

DCI Gives Deadline To Dental Colleges To Upload MDS Students’ Details

Powered by WPeMatico

G Kishan Reddy says Centre will try its best to promote pharma sector in Hyderabad

Hyderabad: The Pharma sector should be encouraged and government in the coming days will try its best to promote the sector, said Union Minister For Coal and Mines, G Kishan Reddy.

The Telangana BJP President was the Chief Guest at the Indian Pharmaceutical Congress (IPC) Expo which was held at Hi-Tech Exhibition Centre Hall, Hitech City in Hyderabad.

vSpeaking with ANI, Reddy said, “Hyderabad has made a big contribution in the sector of pharma. In different parts of the world, India exports vaccines. During the Covid-19 time, India not only vaccinated its 140 crore population but also exported vaccines to African countries and several poor nations.”

The Union Minister also said that he congratulated the pharma sector, which during the Covid time helped in the production of vaccines. “In the coming days, the Modi government is ready to promote the pharma sector. The pharma sector should be encouraged and in the coming days, we will try our best to promote the sector,” Reddy said.
Taking to his official X handle, Reddy posted about the IPC Expo and said, “Attended and addressed the valedictory function of the 73rd Indian Pharmaceutical Congress (IPC) in Hyderabad.”    
He added further, “IPC has always been a cornerstone event, bringing together thought leaders, industry experts, and innovators. In my address, emphasized how India, under the leadership of Narendra Modi, is emerging as a global pharmaceutical hub. This year’s theme of IPC, ‘Role of Indian Pharma for Global Wellbeing,’ highlights India’s significant contributions to global health.”
The Union Minister also urged pharmaceutical stakeholders to strengthen Hyderabad’s brand as a pharmacy of the world. In another post, he said, “With institutions like National Animal Resource Facility for Biomedical Research (NARFBR) established by the Government of India and other cutting-edge universities, Hyderabad boasts a robust research ecosystem conducive to biomedical innovation, aiming to develop India and Hyderabad as pivotal players in the global biomedical industry.”

Read also: Indian pharma firms seek tax incentives to boost innovation

Powered by WPeMatico

No doubt NEET PAPER LEAK took place, Sanctity Was Compromised: Supreme Court

New Delhi: While considering the pleas seeking cancellation of the National Eligibility-and-Entrance Test Undergraduate (NEET-UG) 2024 examination, the Supreme Court on Monday said that undoubtedly the NEET paper leak took place and the sanctity of the exam was compromised. 

Further, observing that cancelling the entire exam might affect 24 lakh students who appeared in the exam, the Apex Court bench comprising the CJI has asked the National Testing Agency and the Union Government to identify the red flags and to find out whether the paper leak took place at a systemic level and if the beneficiaries or the likely beneficiaries of the paper leak could be identified.

In this regard, the Apex Court bench hinted at the possibility of holding a ‘limited retest’ for those who were beneficiaries of the paper leak. Further, the Apex Court also sought to know from the NTA and the Govt about the actions taken to identify the beneficiaries of the paper leak.

“The fact that there was a leakage of question papers cannot be disputed. Now, what is the consequence of that leak would depend on the nature of that leak,” observed the Chief Justice.

“You don’t cancel an examination merely because two students have committed a malpractice … Before we order a retest, we must be careful – what is the nature of that leak? We are dealing with careers of 23 lakh students. Asking 23 lakhs students to re-appear for an examination, together with the preparation, cost, travel, and dislocation of admission schedules …” the CJI further observed.

“What is the modality in which the leak took place? If the modality of the leak is through electronic means and social media, then there is a possibility that the leak is widespread,” the Chief Justice further added.

Asking the Union Government and the National Testing Agency (NTA) to respond to some specific queries by Wednesday, the Apex Court bench posted the matter for further hearing on Thursday i.e. July 11, 2024.

NTA has been asked to clarify when the leak took place, the manner in which the question papers were disseminated, time duration between the leak and the exam may on 5th May etc. The Court has also sought to know from the Agency regarding the steps taken to identify the beneficiaries of the leak, the steps taken by NTA to identify the centres/cities where the leaks took place and the modalities followed to identify the beneficiaries and also how the leak was disseminated.

Apart from this, the Apex Court bench has also asked the Central Bureau of Investigation, which is currently probing the allegations of the paper leak in the undergraduate medical entrance exam, to file a status report by Wednesday.

Further, the Court advised the Government to set up a multi-disciplinary committee to ensure measures to put a stop to any paper leak instances in the future. In case, such a committee has already been created, the Apex Court bench sought to know the details of the same.

“It would be necessary for the government to set up a multi disciplinary team of renowned experts to ensure due measures are taken to obviate any further breach in NEET. The constitution of the committee shall be informed to the Court and the Court shall decide if the committee shall go ahead or would someone be needed to ensure people from a diverse pool of domain expertise and data analytics,” the Court noted.

Also taking note of the multiple number of pleas filed in this connection and the huge number of lawyers appearing for those pleas, the Supreme Court bench has asked all the counsels for the petitioners seeking a retest of the NEET UG 2024 exam to submit a consolidated document not exceeding 10 pages.

What Happened at the Hearing Today?

When the NEET-related issues came up for hearing before the Supreme Court today i.e. on 8th July 2024, Gujarat-based students submitted their plea of opposing any petitions for cancelling NEET.

The bench observed that they would consider the pleas first asking for a retest because they were challenging the entirety of the test. “After hearing them, we will hear the NTA and the Govt,” the bench observed.

Meanwhile, a counsel appearing for the NEET aspirants from Meghalaya submitted that the petitioners concerned were given the papers for 40 minutes. Despite this, they were allegedly not on the list of 1563 students who were given the opportunity for a retest. However, the Government denied such allegations.

“We will start at 2’o clock. We will hear counsels for the petitioners. Then we will hear individuals who have slightly different nuanced positions. We will hear everybody. There is no difficulty,” the bench mentioned, adding that it would consider the pleas of those who challenged the entirety of the examination and demanded a retest, because that is the “broadest argument”.

When the pleas seeking NEET retest came up for hearing at 2.00 PM, the counsel for the petitioners referred to the arrests made by the Bihar police for leaking the question papers through the Telegram app. Further, the counsel highlighted that 67 NEET candidates received full marks in the exam.

The counsel for the petitioners argued that if faults were found at a systemic level and if it was impossible segregating the wrongdoers from those who were innocents, the entire exam had to be set aside.

He further submitted that as per Bihar police, NTA did not follow standard SOP, indicating a systemic fault and a large-scale fraud. The counsel also referred to the NTA’s statement saying that it was unsure whether the fault was at a systemic level. At this outset, the counsel further referred to the NTA’s claim that the fraud was at a “minuscule” level and highlighted the contradictory stands of the agency.

Stressing on the claim of a large scape paper leak and irregularities in the NEET UG 2024 exam, the counsel for the petitioners submitted before the Supreme Court that there were 6 FIRs registered in Bihar, Delhi, Rajasthan, Gujarat, Maharashtra and Jharkhand in relation to the NEET scam.

When the Apex Court bench expressed doubts that whether the alleged paper leak affected the entire exam across the country, the counsel for the petitioners replied that the question papers were being circulated in the Telegram channel on May 3rd and 4th, ahead of the exam held on 5th May, 2024.

At this outset, the bench asked the National Testing Agency regarding the number of candidates appearing in the exam, the number of exam centres, and the manner in which the question papers were sent to the centres.

Responding to these queries, the counsel for NTA submitted that 23,33,297 students appeared in the exam in more than 4751 centres in 571 cities. The bench also took note of the fact that several centres were situated abroad. Thereafter the bench further questioned the NTA regarding how the question papers were prepared, sought to know the time when the papers were sent to the printing presses and further process of how the papers were taken to the exam centres etc.

“Why we are asking – if we come to the conclusion that the time lag between the leak and the actual date of the examination is relatively limited, then that would be a circumstance which would militate against holding a retest. If that time lag between the leak and the exam is wider, then there is a greater chance there are malaises across the system. If it appears that the question papers were leaked on the morning of the 5th (May) – exam was scheduled at 2 o clock, students were made to memorise – that may be indication that the leak was not as widespread,” observed the CJI.

Observing that there was no doubt that a leak had taken place, the bench clarified that a retest had to be ordered if the sanctity of the exam had been lost, if it was impossible to identify the wrongdoers. “If you can’t distinguish the grain from the chaff, the tainted from the untainted, then a re-test has to be ordered,” the CJI observed.

On the other hand, the bench highlighted that the decision affects the future of 23 lakh students and observed that it was necessary to ascertain the modality of the leak. For instance, it noted that if the leak was through the social media, then there was the possibility that the leak was extremely wide.

Asking the authorities to identify the red flags, the CJI referred to some examples of red flags such as securing full marks i.e. 720 marks in the exam. However, it observed that not everyone who scored 720 must be a fraudster and noted that there might still be people who are extraordinarily bright in that 720/720.

“But we found, for the previous years, the proportion is very low. This suddenly goes up to 67. How many of those 720 are from that 1563 candidates who were beneficiaries of grace marks?” questioned the bench.

Another red flag that the Supreme Court bench highlighted was the instances of students registered at one centre and who changed their exam centre to appear in the exam at a far-off place and secured high marks.

According to the Apex Court bench, students securing exceptionally high marks in NEET and scoring low in their 12th exams was also a red flag. However, at this outset, the bench acknowledged the fact that the students study harder for NEET. It also identified the instances of students getting high marks in one subject and abysmally low in another subject as a red flag.

“One thing which is very clear is that the leak has taken place. That the sanctity of the exam has been breached is beyond doubt. The question is how widespread is the leak,” observed the bench.

At this outset, the counsel for the Union Government denied the allegations of leak and submitted that the matter was being investigated. He further relied on a clarification issued by the Bihar police, stating that they had not issued any press note, which was cited by the petitioners.

Taking note of this submission, the CJI questioned, “Is it case of NTA today that there is no leak? We take it that there is a leak, there is no question about it. But the nature of the leak is what we are determining. The fact that there was a leakage of question papers cannot be disputed. Now, what is the consequence of that leak would depend on the nature of that leak.”

However, the bench observed that it could not cancer the exam merely because two students had committed a malpractice. It highlighted the need to be careful to ascertain the nature of the leak noting that the decision would affect 23 lakh candidates.

So, before taking any such decisions, the bench sought to know the nature of the FIRs, how the leak happened, what was the point of time when the leak took place, how it disseminated etc.

“These are important questions. And next, very important – what are the actions which the government of India and NTA had taken to identify the wrong-doings and who are the beneficiaries of the wrong doings?” noted the CJI.

The bench also sought to know how many students whose results were withheld across India as a result of the leak that took place and where are such students located.

“One more thing I want to ask. With the kind of technology we have today at our disposal and the government of India has its cyber forensic unit, is it not possible for us to run, with use of experts, to bring some sort of confidence to the process? That you carry out a detailed data analytics exercise to see if there are suspicious markers? We have to identify what the suspicious markers are. I just want to say one thing. Let us not be in self-denial. Self-denial is only adding to the problem,” added the CJI.

Observing that there should be a multi-disciplinary committee from experts across the country to ensure that that such instances of paper leak would not happen in the future.

“What are we doing to ensure that this will not happen in future and how are we are planning to tighten the exam process. Is there an audit being conducted by government on what went wrong? That is the third aspect. The second aspect, assuming that we are not going to cancel the entire exam, what do we do between today and the date of admissions to identify who are beneficiaries of the fraud. And first aspect, do we cancel the exam or do we allow the counselling to go through by identifying the beneficiaries. On this first aspect we would like to know from the government on identifying who are the beneficiaries of the wrong doing?” the bench observed.

What did the Court order?

On the issue of re-test, the bench ordered, “Whether retest should be there or not is based on settled parameters – the court has to see whether (1) alleged breach took place at the systemic level (2) whether the breach is of a nature which affects integrity of the entire exam process and (3) whether it is possible to segregate the beneficiaries of the fraud from the untainted students. In a situation where breach of sanctity affects entirety of exam and if segregation is not possible then retest is needed. But if beneficiaries are identified then retest wont be needed which involves students on such a large scale.”

Asking NTA to make a full disclosure, the Court asked the agency to clarify on the following issues:

1. When did the leak first took place?

2. The manner in which the question papers leaked were disseminated

3. The duration of time between the leak and the exam held on May 5th.

The agency was also directed to inform the court about the- steps taken by NTA to identify centres/cities in which the leak took place, modalities followed to identify the beneficiaries of the leak, the number of students who have been so far identified.

Apart from this, the Apex Court also asked the Union Government and NTA to inform if it was possible to use the data analytics, either within the cyber forensic unit or any other expert agency to identify the likely wrongdoers. If it could be done, the bench asked the authorities to identify the modalties that could be followed for segregating the tainted from the untainted.

Further, the bench asked the authorities to inform about the status of the counselling and asked the CBI to file a status report before the court on the status of the investigation as of today and material which has come to light.

NEET Controversy: 

This year’s NEET UG 2024 exam was mired in controversies after a paper leak scam came to light. Medical Dialogues had earlier reported that around 13 people, including four examinees and their family members, were arrested in Bihar for their alleged involvement in the paper leak of the NEET-UG exam. Patna police sources had previously claimed that the NEET-UG question papers along with their answers were provided to around 20 aspirants a day before the date of the exam i.e. May 5, 2024.

Then, the Economic Offences Unit (EOU) of Bihar Police, which took over the investigation, revealed that the brokers involved in the NEET paper leak scam took between Rs 30 lakh to Rs 50 lakh from each of the medical aspirants in exchange for giving them the question paper of the NEET UG 2024 question paper ahead of the examination.

Multiple pleas have been filed before the High Courts and the Supreme Court seeking an investigation into the alleged paper leak scam. Some of the pleas demanded the scrapping of the NEET UG 2024 exam and holding a retest.

Meanwhile, during the case proceedings, NTA earlier decided to withdraw the grace marks awarded to 1563 candidates and hold an optional retest for those candidates. Those who did not opt for the retest were allowed to retain their original marks, without the grace marks.

The matter is now being investigated by the Central Bureau of Investigation (CBI). Central Government on June 22, 2024, handed over the charge of investigating in the alleged irregularities in the NEET UG 2024 examination to the Central Bureau of Investigation (CBI).

Earlier, while considering the NEET-related pleas, the Supreme Court had refused to defer the counselling/seat allotment process scheduled to commence on July 6. However, the bench had orally observed that the admissions would be subject to the final outcome of the petitions and if the exams were set aside, the counselling would get invalidated consequentially.

The Top Court had also expressed its concern over the alleged discrepancies in the NEET UG 2024 exam. The Court had noted that even ‘0.001& negligence’ in conducting the NEET-UG 2024 exams would be looked into with all seriousness considering the immense labor put in by the candidates for the prestigious examination.

Powered by WPeMatico

Indian pharma firms seek tax incentives to boost innovation

As India anticipates Prime Minister Narendra Modi’s government to present the federal finance budget in July, pharmaceutical companies in the country are rallying for tax incentives and financial support aimed at advancing research on innovative drugs.

The upcoming budget represents Prime Minister Modi’s first policy announcement in his third term as India’s Prime Minister.

Indian drug manufacturers must focus on developing complex drugs beyond the usual generic variety if the country is to continue being renown for being the ‘pharmacy of the world’ for its affordable medicines, experts say.

“If the Indian government can give some income tax exemptions for 5-10 years for any new molecule developed in India…that can pull innovation to grassroot level…companies will start investing in innovation,” Bharat Biotech’s Chairman Krishna Ella told Reuters on the sidelines of an event in Hyderabad on Friday.
Bharat Biotech developed India’s first indigenous Covid-19 vaccine, Covaxin.
India, whose pharmaceutical market is expected to be valued at $130 billion by the end of the decade, is the world’s third largest manufacturer of drugs by volume after the United States and China and is a hub of generic drug manufacturers.
Generic drugs are cheaper versions of brand-name drugs.
In March, research firm Bernstein said that India needs to create a domestic market where innovative drugs can be profitable at the right price.
“Spending millions on clinical trials with no pricing power is not a business they (pharma companies) want to be in,” Bernstein said in an open letter to the prime minister.
The firm also said insurance coverage for novel drugs and harmonising regulatory standards for manufacturing and clinical trials will be required for fostering innovation.
India has offered incentives since 2020 to spur the manufacturing of a broad range of products from drones to drugs in the country. But manufacturers of novel drugs are not eligible for the incentives yet.
“I think government is evaluating on how their existing scheme is working…but industry is expecting a policy from the government to boost research and development in companies,” HIV drugs maker Hetero Drugs’ Chairman Partha Saradhi Reddy told Reuters.
India’s export sales, which dominate the US generics market, is expected to double to $55 billion by 2030, according to a government-backed trade body Pharmaceuticals Export Promotion Council of India (Pharmexcil).
“And if you want to have this flag going high in the entire globe and again…I think probably we have to look a little bit out of the box,” Raja Bhanu, director general of Pharmexcil, said

Read also: Biocon Biologics plans to raise Rs 4,000-4,500 crore via local bonds: Report

Powered by WPeMatico

AIIMS Jammu set to launch OPD services in two weeks: Health Minister Nadda

Jammu: Union Minister of Health and Family Welfare and Chemicals and Fertilizers Shri Jagat Prakash Nadda yesterday visited the All India Institute of Medical Science (AIIMS) Vijaypur in Jammu.

Dr Jitendra Singh, Minister of State (Independent Charge), Ministry of Science & Technology; Ministry of Earth Sciences; Minister of State in the Prime Minister’s Office, Ministry of Personnel, Public Grievances & Pensions; Department of Atomic Energy and Space, Shri Jugal Kishore Sharma, Member of Parliament, Lok Sabha and Member of Institute Body, AIIMS Jammu; Shri Gulam Ali Khatana, Member of Parliament, Rajya Sabha were also present on the occasion.

Also Read:AIIMS Jammu to start OPD services in May

Speaking on the occasion Shri Nadda said that “Under the visionary leadership of Prime Minister Shri Narendra Modi, not just health, but every sector has experienced immense growth”. He added that “Shri Narendra Modi has brought a new wave of comprehensive development into Jammu & Kashmir, advancing the state towards prosperity and growth”.

The Union Health Minister emphasized that it is important to foster collaborative synergy among various branches of medical sciences. He added that both allopathy and Ayurveda possess distinct significance and strengths, complementing each other to enhance healthcare outcomes.

Addressing the Faculty, Residents, Staff and Students of AIIMS Jammu, Shri Nadda encouraged the faculty to persist in their pursuit of knowledge, service and research. The Minister commended their dedication and hard work, emphasizing the importance of continued excellence and innovation in healthcare and education.

He remarked, “AIIMS Jammu is an institution that embodies the aspirations and dreams of countless individuals. It’s a beacon of hope not only for the people of J&K, but also for that of Leh, and other neighboring states like Punjab and Himachal Pradesh”. He assured all the possible help and support to the institution in ensuring better healthcare access for millions. He emphasized that skill & talent should never be compromised and exalted the faculty to work tirelessly to develop an “AIIMS culture which is an amalgam of selflessness, dedication, competency, integrity, innovation and trust.

The Union Minister along with other dignitaries visited various facilities including the Digital Library with e-books, e-journals apart from hard copies of books & professional journals. The distinguished features showcased at the library included carrels for research work, state-of-the-art digital dashboard, automated book issue and deposit device and the RFID security gate at the entrance of the Digital Library.

The Union Health Minister also visited the modern Lecture Theatres for student with state-of-the-art Smart Boards, special features of which were demonstrated to the dignitaries. He expressed his happiness that AIIMS Jammu is incorporating technology advancements in pedagogy at AIIMS Jammu.

The Minister also inspected the Outpatient Department (OPD), including the registration counters and “Indoor Navigation System” for patients.

During the visit, the Union Health Minister observed the world-class facilities and services available to the people of Jammu & Kashmir. He said that with its skilled doctors and aspiring medical professionals, AIIMS Vijaypur is set to enhance healthcare facilities in the region.

Powered by WPeMatico